US 12227740
CBLB endonuclease variants, compositions, and methods of use
granted A61KA61K2239/38A61K40/11
Quick answer
US patent 12227740 (CBLB endonuclease variants, compositions, and methods of use) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K2239/38, A61K40/11, A61K40/31, A61K40/4204